MedTrace Logo

Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

NCT01335074 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2016-11-15

No results posted yet for this study

Summary

Sorafenib is the standard therapy for advanced liver cancer but often shows dose-limiting toxicities with the need to reduce the applied dose of the compound. As this limits the overall response rate of the therapy, a combination with temsirolimus, an inhibitor of mTOR signaling, will be investigated regarding safety and tolerability in patients with advanced liver cancer under a reduced dose of sorafenib.

Conditions

Interventions

DRUG

Temsirolimus + Sorafenib

200mg bid Sorafenib + 15, 20 or 25 mg Temsirolimus

Sponsors & Collaborators

  • Philipps University Marburg

    lead OTHER

Principal Investigators

  • Patrick Michl, MD · Dept. of Gastroenterology

  • Matthias Ocker, MD · Inst. for Surgical Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01335074 on ClinicalTrials.gov